Technical Analysis for CGTX - Cognition Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | -0.90% | |
| Wide Bands | Range Expansion | -0.90% | |
| Oversold Stochastic | Weakness | -0.90% | |
| MACD Bearish Signal Line Cross | Bearish | -4.91% | |
| Inside Day | Range Contraction | -4.91% | |
| Wide Bands | Range Expansion | -4.91% | |
| Gapped Up | Strength | -4.91% | |
| Fell Below 50 DMA | Bearish | -4.60% |
| Alert | Time |
|---|---|
| Down 2 % | about 18 hours ago |
| Down 1% | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Up 5% | about 22 hours ago |
| 5x Volume Pace | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/08/2024
Cognition Therapeutics, Inc. Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Biology Alzheimer's Disease Parkinson's Disease Disorders Dementia Psychiatric Diagnosis Aging Associated Diseases Geriatrics Cognitive Disorders Lewy Body Dementia Dry Age Related Macular Degeneration Early Stage Alzheimer's Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.95 |
| 52 Week Low | 0.34 |
| Average Volume | 547,842 |
| 200-Day Moving Average | 1.40 |
| 50-Day Moving Average | 0.49 |
| 20-Day Moving Average | 0.51 |
| 10-Day Moving Average | 0.50 |
| Average True Range | 0.05 |
| RSI (14) | 41.18 |
| ADX | 14.3 |
| +DI | 24.48 |
| -DI | 25.80 |
| Chandelier Exit (Long, 3 ATRs) | 0.50 |
| Chandelier Exit (Short, 3 ATRs) | 0.58 |
| Upper Bollinger Bands | 0.60 |
| Lower Bollinger Band | 0.42 |
| Percent B (%b) | 0.12 |
| BandWidth | 35.92 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0077 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.50 | ||||
| Resistance 3 (R3) | 0.51 | 0.49 | 0.49 | ||
| Resistance 2 (R2) | 0.49 | 0.47 | 0.49 | 0.49 | |
| Resistance 1 (R1) | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 |
| Pivot Point | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
| Support 1 (S1) | 0.42 | 0.43 | 0.42 | 0.42 | 0.40 |
| Support 2 (S2) | 0.41 | 0.42 | 0.41 | 0.39 | |
| Support 3 (S3) | 0.38 | 0.41 | 0.39 | ||
| Support 4 (S4) | 0.38 |
